Open-label pilot study of injectable naltrexone for cannabis dependence
Background: There are no FDA-approved pharmacotherapies for cannabis use disorders (CUD), despite the evaluation of numerous medications. Notably, chronic dosing of oral naltrexone decreases self-administration of cannabis in human laboratory studies. Objectives: To test the feasibility of long-acti...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor and Francis Ltd
2018
|
Subjects: | |
Online Access: | View Fulltext in Publisher |